A phase II study of daratumumab in patients with high-risk MGUS and low-risk smoldering multiple myeloma

Authors
Category Primary study
JournalBlood
Year 2021
This article has no abstract
Epistemonikos ID: 3ef26fff590f90d39f073178744d824277671813
First added on: Feb 13, 2025